Rob Fried, CEO of Niagen Bioscience, stated, “At the heart of the Niagen Plus ecosystem are our sterile pharmaceutical-grade Niagen NR formulations for IV as well as intramuscular (IM) and ...
“Niagen IV is now offered at over 900 clinics nationwide, including the new iCRYO locations,” stated Rob Fried, CEO of Niagen Bioscience. “This milestone highlights the growing recognition of Niagen ...
Alvotech, Kashiv Biosciences, and Advanz Pharma announced positive results from a confirmatory efficacy study of AVT23 (ADL-018), a proposed biosimilar to Xolair® (omalizumab), conducted on patients ...
Fresh off a pivot from commercial pharma business to preclinical biotech, Aadi Bioscience has rebranded to better match its strategic reboot. The company will henceforth be known as Whitehawk ...
Angelini Pharma secures exclusive global license rights to future identified drug targets Quiver receives undisclosed advance payment and is eligible for future milestone-dependent payments and ...
We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Pacira BioSciences, Inc. (NASDAQ:PCRX) stands against other ...
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best small-cap value stocks to buy. On April 24, H.C.
This Biotech Stock Is Down 65%. How a Cancer Trial Was Ruined by Its Own Design. Compass Therapeutics says a treatment evaluating its cancer treatment didn’t meet the secondary endpoint for an ...
Outperforming NAD+ IV, Niagen IV (patented nicotinamide riboside or NR) provides superior tolerability, a 75% shorter infusion time, and increases NAD+ 20% higher three hours post-infusion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results